{"fetched":"2026-09-17","source":"https://api.openalex.org/works","license":"CC0","papers":{"paper-bray-globocan-2018-cacancer-2018":{"doi":"10.3322/caac.21492","openalexId":"W2889646458","cited":88128,"byYear":{"2012":3,"2013":6,"2014":3,"2015":4,"2016":3,"2017":6,"2018":294,"2019":7552,"2020":19411,"2021":21912,"2022":14575,"2023":10340,"2024":7988,"2025":4926,"2026":992},"year":2018,"title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries"},"paper-alphafold2-jumper-nature-2021":{"doi":"10.1038/s41586-021-03819-2","openalexId":"W3177828909","cited":47299,"byYear":{"2012":7,"2013":4,"2014":1,"2017":2,"2019":2,"2020":19,"2021":1121,"2022":6494,"2023":9978,"2024":11955,"2025":11047,"2026":6638},"year":2021,"title":"Highly accurate protein structure prediction with AlphaFold"},"paper-bray-globocan-2022-cacancer-2024":{"doi":"10.3322/caac.21834","openalexId":"W4393935425","cited":25401,"byYear":{"2012":2,"2017":2,"2018":3,"2019":13,"2020":29,"2021":70,"2022":66,"2023":40,"2024":3791,"2025":14345,"2026":7038},"year":2024,"title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries"},"paper-chen-cancer-statistics-china-2015-cacancer-2016":{"doi":"10.3322/caac.21338","openalexId":"W2272984102","cited":18016,"byYear":{"2015":3,"2016":486,"2017":1649,"2018":2299,"2019":2661,"2020":2968,"2021":2734,"2022":2067,"2023":1386,"2024":1154,"2025":466,"2026":125},"year":2016,"title":"Cancer statistics in China, 2015"},"paper-aaronson-eortc-qlq-c30-jnci-1993":{"doi":"10.1093/jnci/85.5.365","openalexId":"W2167571044","cited":16178,"byYear":{"2012":494,"2013":532,"2014":571,"2015":631,"2016":638,"2017":669,"2018":712,"2019":741,"2020":913,"2021":1173,"2022":1037,"2023":1096,"2024":1176,"2025":953,"2026":657},"year":1993,"title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology"},"paper-coussens-werb-inflammation-cancer-nature-2002":{"doi":"10.1038/nature01322","openalexId":"W1965037168","cited":15220,"byYear":{"2012":686,"2013":749,"2014":776,"2015":774,"2016":757,"2017":773,"2018":746,"2019":821,"2020":869,"2021":942,"2022":906,"2023":879,"2024":759,"2025":591,"2026":290},"year":2002,"title":"Inflammation and cancer"},"paper-al-hajj-breast-cancer-stem-cells-pnas-2003":{"doi":"10.1073/pnas.0530291100","openalexId":"W2023427658","cited":10404,"byYear":{"2012":768,"2013":743,"2014":673,"2015":658,"2016":624,"2017":586,"2018":487,"2019":477,"2020":493,"2021":452,"2022":384,"2023":392,"2024":286,"2025":201,"2026":105},"year":2003,"title":"Prospective identification of tumorigenic breast cancer cells"},"paper-checkmate-057-nejm-2015":{"doi":"10.1056/nejmoa1507643","openalexId":"W2104347254","cited":9539,"byYear":{"2012":1,"2013":3,"2014":3,"2015":41,"2016":688,"2017":1033,"2018":1174,"2019":1133,"2020":1289,"2021":1126,"2022":923,"2023":746,"2024":688,"2025":436,"2026":228},"year":2015,"title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer"},"paper-checkmate-017-nejm-2015":{"doi":"10.1056/nejmoa1504627","openalexId":"W2156353875","cited":8619,"byYear":{"2013":2,"2014":6,"2015":183,"2016":805,"2017":1001,"2018":1070,"2019":974,"2020":1084,"2021":964,"2022":747,"2023":658,"2024":582,"2025":335,"2026":181},"year":2015,"title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer"},"paper-vogelstein-cancer-genome-landscapes-science-2013":{"doi":"10.1126/science.1235122","openalexId":"W2044433401","cited":8148,"byYear":{"2012":2,"2013":198,"2014":541,"2015":681,"2016":719,"2017":777,"2018":755,"2019":709,"2020":682,"2021":671,"2022":682,"2023":515,"2024":513,"2025":406,"2026":279},"year":2013,"title":"Cancer Genome Landscapes"},"paper-conroy-folfirinox-pancreatic-nejm-2011":{"doi":"10.1056/nejmoa1011923","openalexId":"W2151253787","cited":7902,"byYear":{"2012":222,"2013":281,"2014":381,"2015":472,"2016":454,"2017":555,"2018":580,"2019":563,"2020":724,"2021":797,"2022":636,"2023":636,"2024":603,"2025":534,"2026":368},"year":2011,"title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer"},"paper-calle-obesity-cancer-mortality-nejm-2003":{"doi":"10.1056/nejmoa021423","openalexId":"W2141662760","cited":7745,"byYear":{"2012":450,"2013":478,"2014":482,"2015":466,"2016":379,"2017":366,"2018":341,"2019":310,"2020":384,"2021":384,"2022":337,"2023":305,"2024":230,"2025":198,"2026":75},"year":2003,"title":"Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults"},"paper-balkwill-mantovani-inflammation-virchow-lancet-2001":{"doi":"10.1016/s0140-6736(00)04046-0","openalexId":"W2116554142","cited":7738,"byYear":{"2012":305,"2013":371,"2014":413,"2015":390,"2016":384,"2017":453,"2018":382,"2019":434,"2020":476,"2021":461,"2022":455,"2023":442,"2024":376,"2025":278,"2026":159},"year":2001,"title":"Inflammation and cancer: back to Virchow?"},"paper-chen-mellman-cancer-immunity-cycle-immunity-2013":{"doi":"10.1016/j.immuni.2013.07.012","openalexId":"W1994993231","cited":7078,"byYear":{"2013":10,"2014":63,"2015":140,"2016":204,"2017":338,"2018":424,"2019":479,"2020":706,"2021":811,"2022":910,"2023":992,"2024":925,"2025":649,"2026":420},"year":2013,"title":"Oncology Meets Immunology: The Cancer-Immunity Cycle"},"paper-bao-glioma-stem-cells-radioresistance-nature-2006":{"doi":"10.1038/nature05236","openalexId":"W2060551076","cited":6451,"byYear":{"2012":416,"2013":426,"2014":404,"2015":346,"2016":379,"2017":370,"2018":307,"2019":312,"2020":374,"2021":397,"2022":367,"2023":337,"2024":251,"2025":226,"2026":125},"year":2006,"title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response"},"paper-allemani-concord-3-lancet-2018":{"doi":"10.1016/s0140-6736(17)33326-3","openalexId":"W2787553551","cited":6316,"byYear":{"2013":2,"2017":2,"2018":242,"2019":445,"2020":1075,"2021":764,"2022":824,"2023":1002,"2024":862,"2025":644,"2026":447},"year":2018,"title":"Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries"},"paper-binnewies-tumor-immune-microenvironment-natmed-2018":{"doi":"10.1038/s41591-018-0014-x","openalexId":"W2801309958","cited":6313,"byYear":{"2012":1,"2018":49,"2019":263,"2020":609,"2021":805,"2022":990,"2023":905,"2024":987,"2025":924,"2026":770},"year":2018,"title":"Understanding the tumor immune microenvironment (TIME) for effective therapy"},"paper-darnell-jak-stat-science-1994":{"doi":"10.1126/science.8197455","openalexId":"W2029275361","cited":6128,"byYear":{"2012":186,"2013":208,"2014":159,"2015":150,"2016":145,"2017":165,"2018":119,"2019":147,"2020":165,"2021":179,"2022":187,"2023":177,"2024":189,"2025":141,"2026":72},"year":1994,"title":"Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins"},"paper-cella-fact-g-jco-1993":{"doi":"10.1200/jco.1993.11.3.570","openalexId":"W2105258029","cited":6086,"byYear":{"2012":224,"2013":235,"2014":254,"2015":239,"2016":245,"2017":236,"2018":280,"2019":269,"2020":269,"2021":307,"2022":326,"2023":297,"2024":306,"2025":249,"2026":181},"year":1993,"title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure."},"paper-burris-gemcitabine-pancreatic-jco-1997":{"doi":"10.1200/jco.1997.15.6.2403","openalexId":"W1931508686","cited":5921,"byYear":{"2012":296,"2013":274,"2014":316,"2015":352,"2016":292,"2017":303,"2018":270,"2019":240,"2020":250,"2021":284,"2022":208,"2023":176,"2024":135,"2025":115,"2026":63},"year":1997,"title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial."},"paper-depmap-tsherniak-cell-2017":{"doi":"10.1016/j.cell.2017.06.010","openalexId":"W2741508285","cited":3612,"byYear":{"2017":26,"2018":108,"2019":196,"2020":294,"2021":385,"2022":405,"2023":470,"2024":629,"2025":712,"2026":387},"year":2017,"title":"Defining a Cancer Dependency Map"},"paper-checkmate-816-nejm-2022":{"doi":"10.1056/nejmoa2202170","openalexId":"W4223502512","cited":2719,"byYear":{"2022":207,"2023":615,"2024":722,"2025":680,"2026":495},"year":2022,"title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer"},"paper-destiny-breast04-nejm-2022":{"doi":"10.1056/nejmoa2203690","openalexId":"W4281640394","cited":2666,"byYear":{"2017":1,"2022":183,"2023":640,"2024":725,"2025":694,"2026":421},"year":2022,"title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer"},"paper-basch-epro-survival-jama-2017":{"doi":"10.1001/jama.2017.7156","openalexId":"W2620925856","cited":2367,"byYear":{"2014":1,"2017":52,"2018":171,"2019":248,"2020":297,"2021":286,"2022":302,"2023":291,"2024":317,"2025":220,"2026":179},"year":2017,"title":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment"},"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012":{"doi":"10.1056/nejmoa1110557","openalexId":"W2121743767","cited":2101,"byYear":{"2012":76,"2013":168,"2014":147,"2015":169,"2016":174,"2017":146,"2018":142,"2019":119,"2020":161,"2021":169,"2022":140,"2023":140,"2024":140,"2025":105,"2026":99},"year":2012,"title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis"},"paper-doll-hill-smoking-lung-cancer-bmj-1950":{"doi":"10.1136/bmj.2.4682.739","openalexId":"W1998637589","cited":1991,"byYear":{"2012":66,"2013":74,"2014":65,"2015":70,"2016":69,"2017":73,"2018":69,"2019":66,"2020":79,"2021":51,"2022":85,"2023":44,"2024":51,"2025":69,"2026":36},"year":1950,"title":"Smoking and Carcinoma of the Lung"},"paper-clear-nejm-2021":{"doi":"10.1056/nejmoa2035716","openalexId":"W3131063362","cited":1807,"byYear":{"2020":1,"2021":206,"2022":382,"2023":411,"2024":342,"2025":283,"2026":180},"year":2021,"title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma"},"paper-adaura-nejm-2020":{"doi":"10.1056/nejmoa2027071","openalexId":"W3087210493","cited":1804,"byYear":{"2016":1,"2020":23,"2021":260,"2022":391,"2023":392,"2024":286,"2025":290,"2026":159},"year":2020,"title":"Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer"},"paper-ascent-nejm-2021":{"doi":"10.1056/nejmoa2028485","openalexId":"W3156985612","cited":1651,"byYear":{"2021":68,"2022":224,"2023":305,"2024":356,"2025":394,"2026":303},"year":2021,"title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer"},"paper-cercek-dmmr-rectal-nejm-2022":{"doi":"10.1056/nejmoa2201445","openalexId":"W4281732693","cited":1638,"byYear":{"2014":1,"2017":1,"2021":1,"2022":162,"2023":419,"2024":416,"2025":385,"2026":247},"year":2022,"title":"PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer"},"paper-admiral-gilteritinib-flt3-nejm-2019":{"doi":"10.1056/nejmoa1902688","openalexId":"W2982353618","cited":1280,"byYear":{"2019":8,"2020":157,"2021":213,"2022":232,"2023":192,"2024":197,"2025":161,"2026":119},"year":2019,"title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML"},"paper-mathur-ncrp-cancer-statistics-2020":{"doi":"10.1200/go.20.00122","openalexId":"W3042980549","cited":1196,"byYear":{"2020":19,"2021":139,"2022":245,"2023":258,"2024":258,"2025":180,"2026":94},"year":2020,"title":"Cancer Statistics, 2020: Report From National Cancer Registry Programme, India"},"paper-destiny-breast03-nejm-2022":{"doi":"10.1056/nejmoa2115022","openalexId":"W4220964921","cited":1187,"byYear":{"2022":144,"2023":306,"2024":292,"2025":266,"2026":179},"year":2022,"title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer"},"paper-crown-nejm-2020":{"doi":"10.1056/nejmoa2027187","openalexId":"W3101089668","cited":1110,"byYear":{"2019":1,"2020":5,"2021":143,"2022":222,"2023":210,"2024":216,"2025":189,"2026":121},"year":2020,"title":"First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer"},"paper-dynamic-nejm-2022":{"doi":"10.1056/nejmoa2200075","openalexId":"W4281738617","cited":1067,"byYear":{"2021":1,"2022":92,"2023":233,"2024":268,"2025":249,"2026":224},"year":2022,"title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer"},"paper-cll14-venetoclax-obinutuzumab-nejm-2019":{"doi":"10.1056/nejmoa1815281","openalexId":"W2948436219","cited":875,"byYear":{"2013":2,"2019":45,"2020":143,"2021":183,"2022":135,"2023":114,"2024":101,"2025":84,"2026":66},"year":2019,"title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions"},"paper-cartitude-4-cilta-cel-nejm-2023":{"doi":"10.1056/nejmoa2303379","openalexId":"W4379375986","cited":812,"byYear":{"2023":61,"2024":238,"2025":283,"2026":228},"year":2023,"title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma"},"paper-echelon-1-brentuximab-avd-nejm-2018":{"doi":"10.1056/nejmoa1708984","openalexId":"W2775803967","cited":792,"byYear":{"2016":1,"2017":4,"2018":84,"2019":96,"2020":127,"2021":95,"2022":84,"2023":83,"2024":85,"2025":66,"2026":64},"year":2017,"title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma"},"paper-alcohol-cancer-burden-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00279-5","openalexId":"W3183035192","cited":697,"byYear":{"2021":28,"2022":86,"2023":138,"2024":206,"2025":143,"2026":96},"year":2021,"title":"Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study"},"paper-detect-a-science-2020":{"doi":"10.1126/science.abb9601","openalexId":"W3020301997","cited":680,"byYear":{"2020":45,"2021":114,"2022":126,"2023":107,"2024":104,"2025":115,"2026":68},"year":2020,"title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention"},"paper-dellphi-301-nejm-2023":{"doi":"10.1056/nejmoa2307980","openalexId":"W4387799038","cited":572,"byYear":{"2023":6,"2024":125,"2025":240,"2026":201},"year":2023,"title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer"},"paper-checkmate-067-10-year-nejm-2025":{"doi":"10.1056/nejmoa2407417","openalexId":"W7211992165","cited":16,"byYear":{"2026":16},"year":2025,"title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma"},"paper-agile-ivosidenib-azacitidine-nejm-2022":{"doi":"10.1056/nejmoa2117344","openalexId":"W4224290890","cited":510,"byYear":{"2019":1,"2022":56,"2023":122,"2024":127,"2025":131,"2026":73},"year":2022,"title":"Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia"},"paper-capp2-aspirin-lynch-lancet-2020":{"doi":"10.1016/s0140-6736(20)30366-4","openalexId":"W3034846243","cited":427,"byYear":{"2020":20,"2021":56,"2022":64,"2023":88,"2024":63,"2025":79,"2026":56},"year":2020,"title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial"},"paper-codebreak-300-nejm-2023":{"doi":"10.1056/nejmoa2308795","openalexId":"W4387859726","cited":375,"byYear":{"2023":7,"2024":125,"2025":144,"2026":99},"year":2023,"title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C"},"paper-challenge-exercise-nejm-2025":{"doi":"10.1056/nejmoa2502760","openalexId":"W4410927245","cited":338,"byYear":{"2024":1,"2025":101,"2026":236},"year":2025,"title":"Structured Exercise after Adjuvant Chemotherapy for Colon Cancer"},"paper-adriatic-nejm-2024":{"doi":"10.1056/nejmoa2404873","openalexId":"W4402519167","cited":335,"byYear":{"2022":1,"2024":27,"2025":164,"2026":143},"year":2024,"title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer"},"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024":{"doi":"10.1056/nejmoa2312948","openalexId":"W4400940914","cited":265,"byYear":{"2024":24,"2025":132,"2026":109},"year":2024,"title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults"},"paper-pramesh-ncg-pooled-procurement-2023":{"doi":"10.2471/blt.23.289714","openalexId":"W4386209307","cited":21,"byYear":{"2023":1,"2024":6,"2025":10,"2026":4},"year":2023,"title":"A National Cancer Grid pooled procurement initiative, India"},"paper-jemal-global-cancer-statistics-2011-cacancer":{"doi":"10.3322/caac.20107","openalexId":"W2106787323","cited":55081,"byYear":{"2012":3951,"2013":5263,"2014":6002,"2015":6182,"2016":5167,"2017":4541,"2018":4036,"2019":3624,"2020":3076,"2021":2353,"2022":1130,"2023":793,"2024":564,"2025":321,"2026":87},"year":2011,"title":"Global cancer statistics"},"paper-ferlay-globocan-2012-methods-ijc-2015":{"doi":"10.1002/ijc.29210","openalexId":"W1757407923","cited":29159,"byYear":{"2012":18,"2013":146,"2014":220,"2015":1201,"2016":2445,"2017":3774,"2018":4606,"2019":4368,"2020":3679,"2021":3001,"2022":2127,"2023":1485,"2024":1145,"2025":638,"2026":250},"year":2014,"title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012"},"paper-hodi-ipilimumab-melanoma-nejm-2010":{"doi":"10.1056/nejmoa1003466","openalexId":"W2097995306","cited":15286,"byYear":{"2012":695,"2013":896,"2014":1025,"2015":1265,"2016":1260,"2017":1289,"2018":1217,"2019":1102,"2020":1191,"2021":1174,"2022":905,"2023":918,"2024":798,"2025":590,"2026":351},"year":2010,"title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma"},"paper-esteva-skin-cancer-deep-learning-nature-2017":{"doi":"10.1038/nature21056","openalexId":"W2581082771","cited":14361,"byYear":{"2012":1,"2014":3,"2015":2,"2016":2,"2017":276,"2018":886,"2019":1366,"2020":1717,"2021":1792,"2022":1523,"2023":1592,"2024":1738,"2025":2080,"2026":1369},"year":2017,"title":"Dermatologist-level classification of skin cancer with deep neural networks"},"paper-jemal-cancer-statistics-2010-cacancer-2010":{"doi":"10.3322/caac.20073","openalexId":"W2158734599","cited":12621,"byYear":{"2012":2614,"2013":1697,"2014":1235,"2015":935,"2016":709,"2017":544,"2018":449,"2019":436,"2020":357,"2021":301,"2022":185,"2023":139,"2024":120,"2025":64,"2026":15},"year":2010,"title":"Cancer Statistics, 2010"},"paper-hurwitz-bevacizumab-crc-nejm-2004":{"doi":"10.1056/nejmoa032691","openalexId":"W2157769714","cited":11023,"byYear":{"2012":715,"2013":666,"2014":606,"2015":521,"2016":462,"2017":423,"2018":322,"2019":290,"2020":296,"2021":266,"2022":273,"2023":285,"2024":266,"2025":164,"2026":109},"year":2004,"title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer"},"paper-grivennikov-immunity-inflammation-cancer-cell-2010":{"doi":"10.1016/j.cell.2010.01.025","openalexId":"W2118278569","cited":10853,"byYear":{"2012":404,"2013":512,"2014":521,"2015":602,"2016":717,"2017":812,"2018":779,"2019":788,"2020":880,"2021":963,"2022":940,"2023":779,"2024":749,"2025":627,"2026":397},"year":2010,"title":"Immunity, Inflammation, and Cancer"},"paper-keynote-024-nejm-2016":{"doi":"10.1056/nejmoa1606774","openalexId":"W2527905628","cited":10265,"byYear":{"2013":2,"2014":2,"2015":2,"2016":46,"2017":725,"2018":1135,"2019":1156,"2020":1356,"2021":1362,"2022":1152,"2023":1053,"2024":1000,"2025":759,"2026":494},"year":2016,"title":"Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer"},"paper-kalluri-weinberg-emt-basics-jci-2009":{"doi":"10.1172/jci39104","openalexId":"W2154589460","cited":10225,"byYear":{"2012":436,"2013":490,"2014":593,"2015":679,"2016":710,"2017":832,"2018":751,"2019":834,"2020":757,"2021":804,"2022":744,"2023":708,"2024":594,"2025":483,"2026":255},"year":2009,"title":"The basics of epithelial-mesenchymal transition"},"paper-jemal-cancer-statistics-2008-cacancer-2008":{"doi":"10.3322/ca.2007.0010","openalexId":"W2043103956","cited":10213,"byYear":{"2012":762,"2013":696,"2014":510,"2015":485,"2016":376,"2017":295,"2018":272,"2019":244,"2020":184,"2021":141,"2022":115,"2023":83,"2024":76,"2025":49,"2026":12},"year":2008,"title":"Cancer Statistics, 2008"},"paper-hallmarks-new-dimensions-cancer-discov-2022":{"doi":"10.1158/2159-8290.cd-21-1059","openalexId":"W4206662285","cited":9737,"byYear":{"2019":1,"2021":4,"2022":1014,"2023":2043,"2024":2711,"2025":2345,"2026":1617},"year":2022,"title":"Hallmarks of Cancer: New Dimensions"},"paper-jemal-cancer-statistics-2009-cacancer-2009":{"doi":"10.3322/caac.20006","openalexId":"W2101995865","cited":9731,"byYear":{"2012":1178,"2013":849,"2014":697,"2015":523,"2016":411,"2017":355,"2018":229,"2019":198,"2020":180,"2021":149,"2022":108,"2023":92,"2024":78,"2025":50,"2026":13},"year":2009,"title":"Cancer Statistics, 2009"},"paper-el-deiry-waf1-p21-cell-1993":{"doi":"10.1016/0092-8674(93)90500-p","openalexId":"W2015519364","cited":8404,"byYear":{"2012":215,"2013":179,"2014":183,"2015":178,"2016":164,"2017":141,"2018":121,"2019":130,"2020":129,"2021":142,"2022":109,"2023":143,"2024":95,"2025":90,"2026":39},"year":1993,"title":"WAF1, a potential mediator of p53 tumor suppression"},"paper-hollstein-p53-mutations-science-1991":{"doi":"10.1126/science.1905840","openalexId":"W2042316019","cited":8119,"byYear":{"2012":215,"2013":212,"2014":221,"2015":172,"2016":149,"2017":145,"2018":125,"2019":121,"2020":125,"2021":124,"2022":123,"2023":99,"2024":75,"2025":52,"2026":19},"year":1991,"title":"p53 Mutations in Human Cancers"},"paper-gerlinger-intratumour-heterogeneity-nejm-2012":{"doi":"10.1056/nejmoa1113205","openalexId":"W2150575159","cited":7899,"byYear":{"2012":327,"2013":627,"2014":682,"2015":696,"2016":741,"2017":675,"2018":645,"2019":550,"2020":561,"2021":597,"2022":538,"2023":368,"2024":318,"2025":299,"2026":252},"year":2012,"title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing"},"paper-ferlay-globocan-2018-methods-ijc-2019":{"doi":"10.1002/ijc.31937","openalexId":"W2895926103","cited":7811,"byYear":{"2012":1,"2014":1,"2015":1,"2016":1,"2018":14,"2019":426,"2020":1461,"2021":1861,"2022":1399,"2023":1012,"2024":894,"2025":514,"2026":214},"year":2018,"title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods"},"paper-imbrave150-nejm-2020":{"doi":"10.1056/nejmoa1915745","openalexId":"W3025022288","cited":7514,"byYear":{"2014":1,"2016":2,"2019":1,"2020":296,"2021":1040,"2022":1296,"2023":1373,"2024":1351,"2025":1263,"2026":881},"year":2020,"title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma"},"paper-jemal-cancer-statistics-2007-cacancer-2007":{"doi":"10.3322/canjclin.57.1.43","openalexId":"W1965734230","cited":7487,"byYear":{"2012":420,"2013":331,"2014":332,"2015":221,"2016":196,"2017":181,"2018":117,"2019":101,"2020":146,"2021":126,"2022":95,"2023":113,"2024":76,"2025":34,"2026":13},"year":2007,"title":"Cancer Statistics, 2007"},"paper-keynote-189-nejm-2018":{"doi":"10.1056/nejmoa1801005","openalexId":"W2796582438","cited":6750,"byYear":{"2013":1,"2015":1,"2016":1,"2017":2,"2018":286,"2019":679,"2020":988,"2021":1090,"2022":924,"2023":848,"2024":853,"2025":651,"2026":413},"year":2018,"title":"Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer"},"paper-keynote-010-lancet-2016":{"doi":"10.1016/s0140-6736(15)01281-7","openalexId":"W2198093519","cited":6575,"byYear":{"2013":1,"2014":4,"2015":5,"2016":281,"2017":615,"2018":820,"2019":850,"2020":946,"2021":836,"2022":650,"2023":551,"2024":546,"2025":312,"2026":146},"year":2015,"title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial"},"paper-galon-immune-contexture-colorectal-science-2006":{"doi":"10.1126/science.1129139","openalexId":"W2142300779","cited":6568,"byYear":{"2012":237,"2013":279,"2014":266,"2015":374,"2016":394,"2017":410,"2018":444,"2019":416,"2020":552,"2021":588,"2022":474,"2023":454,"2024":367,"2025":279,"2026":199},"year":2006,"title":"Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome"},"paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017":{"doi":"10.1001/jamaoncol.2016.5688","openalexId":"W2560322684","cited":6332,"byYear":{"2013":3,"2014":1,"2015":2,"2016":1,"2017":208,"2018":602,"2019":901,"2020":1138,"2021":1127,"2022":838,"2023":651,"2024":507,"2025":281,"2026":66},"year":2016,"title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015"},"paper-keynote-001-pembrolizumab-nsclc-nejm-2015":{"doi":"10.1056/nejmoa1501824","openalexId":"W1982488143","cited":6294,"byYear":{"2013":1,"2014":3,"2015":170,"2016":607,"2017":684,"2018":661,"2019":657,"2020":736,"2021":706,"2022":580,"2023":527,"2024":427,"2025":347,"2026":180},"year":2015,"title":"Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer"},"paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015":{"doi":"10.1056/nejmoa1503093","openalexId":"W2152897456","cited":5928,"byYear":{"2013":2,"2014":5,"2015":188,"2016":628,"2017":758,"2018":677,"2019":573,"2020":672,"2021":580,"2022":493,"2023":448,"2024":393,"2025":301,"2026":197},"year":2015,"title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma"},"paper-ferlay-cancer-statistics-2020-overview-ijc-2021":{"doi":"10.1002/ijc.33588","openalexId":"W3147142721","cited":5817,"byYear":{"2020":1,"2021":242,"2022":1045,"2023":1390,"2024":1503,"2025":1097,"2026":532},"year":2021,"title":"Cancer statistics for the year 2020: An overview"},"paper-eliana-tisagenlecleucel-nejm-2018":{"doi":"10.1056/nejmoa1709866","openalexId":"W2787301955","cited":5804,"byYear":{"2012":1,"2013":1,"2018":242,"2019":496,"2020":719,"2021":811,"2022":809,"2023":762,"2024":786,"2025":676,"2026":490},"year":2018,"title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia"},"paper-flaura-nejm-2018":{"doi":"10.1056/nejmoa1713137","openalexId":"W2770828094","cited":5457,"byYear":{"2016":2,"2017":8,"2018":277,"2019":537,"2020":669,"2021":703,"2022":712,"2023":629,"2024":727,"2025":696,"2026":486},"year":2017,"title":"Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer"},"paper-druker-imatinib-phase1-nejm-2001":{"doi":"10.1056/nejm200104053441401","openalexId":"W2329648702","cited":5284,"byYear":{"2012":251,"2013":237,"2014":184,"2015":180,"2016":163,"2017":163,"2018":134,"2019":138,"2020":132,"2021":130,"2022":149,"2023":127,"2024":106,"2025":107,"2026":86},"year":2001,"title":"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia"},"paper-jaiswal-chip-nejm-2014":{"doi":"10.1056/nejmoa1408617","openalexId":"W2149858388","cited":4882,"byYear":{"2012":3,"2013":1,"2014":6,"2015":151,"2016":242,"2017":302,"2018":360,"2019":391,"2020":469,"2021":533,"2022":552,"2023":543,"2024":516,"2025":448,"2026":354},"year":2014,"title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes"},"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019":{"doi":"10.1056/nejmoa1804980","openalexId":"W2903062212","cited":4151,"byYear":{"2012":2,"2013":1,"2015":1,"2018":3,"2019":219,"2020":514,"2021":648,"2022":699,"2023":608,"2024":620,"2025":504,"2026":319},"year":2018,"title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma"},"paper-body-fatness-iarc-nejm-2016":{"doi":"10.1056/nejmsr1606602","openalexId":"W2510411424","cited":3642,"byYear":{"2015":1,"2016":26,"2017":143,"2018":223,"2019":295,"2020":378,"2021":462,"2022":449,"2023":474,"2024":492,"2025":404,"2026":288},"year":2016,"title":"Body Fatness and Cancer — Viewpoint of the IARC Working Group"},"paper-iris-imatinib-nejm-2003":{"doi":"10.1056/nejmoa022457","openalexId":"W2028959752","cited":3585,"byYear":{"2012":220,"2013":195,"2014":149,"2015":150,"2016":148,"2017":147,"2018":112,"2019":130,"2020":106,"2021":112,"2022":105,"2023":100,"2024":74,"2025":76,"2026":48},"year":2003,"title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia"},"paper-iwai-pdl1-tumour-escape-pnas-2002":{"doi":"10.1073/pnas.192461099","openalexId":"W2063264144","cited":3232,"byYear":{"2012":69,"2013":97,"2014":82,"2015":185,"2016":187,"2017":203,"2018":220,"2019":259,"2020":279,"2021":281,"2022":281,"2023":262,"2024":246,"2025":171,"2026":98},"year":2002,"title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade"},"paper-keynote-177-nejm-2020":{"doi":"10.1056/nejmoa2017699","openalexId":"W3110528877","cited":3113,"byYear":{"2012":1,"2020":4,"2021":376,"2022":581,"2023":617,"2024":568,"2025":538,"2026":423},"year":2020,"title":"Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer"},"paper-doll-peto-50-year-doctors-bmj-2004":{"doi":"10.1136/bmj.38142.554479.ae","openalexId":"W4292672078","cited":2956,"byYear":{"2012":161,"2013":182,"2014":147,"2015":167,"2016":151,"2017":134,"2018":157,"2019":136,"2020":164,"2021":135,"2022":133,"2023":140,"2024":138,"2025":81,"2026":72},"year":2004,"title":"Mortality in relation to smoking: 50 years' observations on male British doctors"},"paper-katherine-nejm-2019":{"doi":"10.1056/nejmoa1814017","openalexId":"W2902218997","cited":2677,"byYear":{"2017":1,"2018":1,"2019":160,"2020":327,"2021":413,"2022":430,"2023":410,"2024":397,"2025":320,"2026":210},"year":2018,"title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer"},"paper-ino-vate-inotuzumab-all-nejm-2016":{"doi":"10.1056/nejmoa1509277","openalexId":"W2419639370","cited":1407,"byYear":{"2015":2,"2016":23,"2017":118,"2018":127,"2019":169,"2020":166,"2021":145,"2022":161,"2023":137,"2024":130,"2025":131,"2026":91},"year":2016,"title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia"},"paper-sankaranarayanan-hpv-screening-nejm-2009":{"doi":"10.1056/nejmoa0808516","openalexId":"W2130297731","cited":1298,"byYear":{"2012":113,"2013":93,"2014":80,"2015":93,"2016":66,"2017":76,"2018":64,"2019":70,"2020":60,"2021":72,"2022":48,"2023":57,"2024":58,"2025":56,"2026":34},"year":2009,"title":"HPV Screening for Cervical Cancer in Rural India"},"paper-dcruz-elective-neck-dissection-nejm-2015":{"doi":"10.1056/nejmoa1506007","openalexId":"W2283809829","cited":1221,"byYear":{"2014":3,"2015":23,"2016":76,"2017":71,"2018":89,"2019":128,"2020":132,"2021":144,"2022":105,"2023":137,"2024":113,"2025":102,"2026":96},"year":2015,"title":"Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer"},"paper-keynote-522-nejm-2022":{"doi":"10.1056/nejmoa2112651","openalexId":"W4210957314","cited":1219,"byYear":{"2022":157,"2023":267,"2024":315,"2025":270,"2026":210},"year":2022,"title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer"},"paper-ev-302-nejm-2024":{"doi":"10.1056/nejmoa2312117","openalexId":"W4392498919","cited":1063,"byYear":{"2021":1,"2024":230,"2025":474,"2026":357},"year":2024,"title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer"},"paper-sankaranarayanan-oral-screening-lancet-2005":{"doi":"10.1016/s0140-6736(05)66658-5","openalexId":"W2109042771","cited":852,"byYear":{"2012":32,"2013":33,"2014":41,"2015":42,"2016":52,"2017":26,"2018":53,"2019":55,"2020":62,"2021":55,"2022":50,"2023":59,"2024":53,"2025":54,"2026":39},"year":2005,"title":"Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial"},"paper-indigo-nejm-2023":{"doi":"10.1056/nejmoa2304194","openalexId":"W4379284101","cited":784,"byYear":{"2015":1,"2022":1,"2023":64,"2024":250,"2025":270,"2026":194},"year":2023,"title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma"},"paper-hpv-vaccine-england-lancet-2021":{"doi":"10.1016/s0140-6736(21)02178-4","openalexId":"W3209481766","cited":781,"byYear":{"2021":12,"2022":153,"2023":155,"2024":183,"2025":168,"2026":109},"year":2021,"title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study"},"paper-karmma-3-ide-cel-nejm-2023":{"doi":"10.1056/nejmoa2213614","openalexId":"W4319812103","cited":766,"byYear":{"2013":1,"2023":102,"2024":249,"2025":236,"2026":174},"year":2023,"title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma"},"paper-gap70-geriatric-assessment-lancet-2021":{"doi":"10.1016/s0140-6736(21)01789-x","openalexId":"W3209480926","cited":590,"byYear":{"2021":4,"2022":110,"2023":130,"2024":150,"2025":103,"2026":92},"year":2021,"title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study"},"paper-galaxy-signatera-nat-med-2023":{"doi":"10.1038/s41591-022-02115-4","openalexId":"W4316507345","cited":510,"byYear":{"2021":1,"2022":1,"2023":68,"2024":171,"2025":161,"2026":108},"year":2023,"title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer"},"paper-ibis-i-tamoxifen-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(14)71171-4","openalexId":"W2161387798","cited":466,"byYear":{"2014":1,"2015":36,"2016":44,"2017":41,"2018":43,"2019":37,"2020":44,"2021":48,"2022":38,"2023":47,"2024":36,"2025":35,"2026":15},"year":2014,"title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial"},"paper-drug-dosing-conundrum-nejm-2021":{"doi":"10.1056/nejmp2109826","openalexId":"W3204811815","cited":291,"byYear":{"2021":3,"2022":46,"2023":76,"2024":75,"2025":55,"2026":36},"year":2021,"title":"The Drug-Dosing Conundrum in Oncology — When Less Is More"},"paper-lynch-frameshift-vaccine-ccr-2020":{"doi":"10.1158/1078-0432.ccr-19-3517","openalexId":"W3035696000","cited":146,"byYear":{"2020":3,"2021":20,"2022":18,"2023":38,"2024":24,"2025":22,"2026":21},"year":2020,"title":"A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial"},"paper-parkin-global-cancer-statistics-2002-cacancer-2005":{"doi":"10.3322/canjclin.55.2.74","openalexId":"W2020830322","cited":18421,"byYear":{"2012":1589,"2013":1537,"2014":1311,"2015":1117,"2016":924,"2017":793,"2018":722,"2019":561,"2020":655,"2021":495,"2022":330,"2023":262,"2024":181,"2025":107,"2026":39},"year":2005,"title":"Global Cancer Statistics, 2002"},"paper-pardoll-immune-checkpoint-blockade-nrc-2012":{"doi":"10.1038/nrc3239","openalexId":"W2066671159","cited":13950,"byYear":{"2012":39,"2013":241,"2014":337,"2015":644,"2016":896,"2017":1143,"2018":1191,"2019":1230,"2020":1446,"2021":1507,"2022":1344,"2023":1249,"2024":1219,"2025":908,"2026":537},"year":2012,"title":"The blockade of immune checkpoints in cancer immunotherapy"},"paper-nlst-nejm-2011":{"doi":"10.1056/nejmoa1102873","openalexId":"W130099911","cited":11237,"byYear":{"2012":376,"2013":498,"2014":529,"2015":607,"2016":596,"2017":593,"2018":725,"2019":766,"2020":933,"2021":981,"2022":958,"2023":1001,"2024":1013,"2025":884,"2026":622},"year":2011,"title":"Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening"},"paper-reya-cancer-stem-cells-nature-2001":{"doi":"10.1038/35102167","openalexId":"W2102085111","cited":9760,"byYear":{"2012":649,"2013":647,"2014":628,"2015":644,"2016":544,"2017":549,"2018":435,"2019":452,"2020":428,"2021":427,"2022":345,"2023":356,"2024":279,"2025":180,"2026":80},"year":2001,"title":"Stem cells, cancer, and cancer stem cells"},"paper-le-mmr-deficiency-pd1-nejm-2015":{"doi":"10.1056/nejmoa1500596","openalexId":"W1940241680","cited":9565,"byYear":{"2013":1,"2014":5,"2015":167,"2016":673,"2017":881,"2018":942,"2019":921,"2020":1168,"2021":1191,"2022":1021,"2023":915,"2024":731,"2025":582,"2026":356},"year":2015,"title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency"},"paper-mani-emt-stem-cell-properties-cell-2008":{"doi":"10.1016/j.cell.2008.03.027","openalexId":"W2014691022","cited":8775,"byYear":{"2012":599,"2013":656,"2014":681,"2015":689,"2016":631,"2017":640,"2018":554,"2019":519,"2020":564,"2021":577,"2022":468,"2023":391,"2024":283,"2025":253,"2026":112},"year":2008,"title":"The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells"},"paper-lamouille-emt-molecular-mechanisms-nrmcb-2014":{"doi":"10.1038/nrm3758","openalexId":"W1964847767","cited":8290,"byYear":{"2013":1,"2014":113,"2015":335,"2016":550,"2017":692,"2018":722,"2019":760,"2020":935,"2021":947,"2022":868,"2023":745,"2024":781,"2025":519,"2026":317},"year":2014,"title":"Molecular mechanisms of epithelial–mesenchymal transition"},"paper-quail-joyce-microenvironment-metastasis-natmed-2013":{"doi":"10.1038/nm.3394","openalexId":"W2033278321","cited":8254,"byYear":{"2012":2,"2013":4,"2014":110,"2015":289,"2016":375,"2017":472,"2018":555,"2019":617,"2020":786,"2021":966,"2022":1079,"2023":921,"2024":942,"2025":709,"2026":422},"year":2013,"title":"Microenvironmental regulation of tumor progression and metastasis"},"paper-rizvi-mutational-landscape-pd1-science-2015":{"doi":"10.1126/science.aaa1348","openalexId":"W2049553585","cited":8011,"byYear":{"2014":1,"2015":216,"2016":618,"2017":768,"2018":887,"2019":882,"2020":998,"2021":983,"2022":886,"2023":629,"2024":515,"2025":393,"2026":216},"year":2015,"title":"Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer"},"paper-lemmon-schlessinger-rtk-signalling-cell-2010":{"doi":"10.1016/j.cell.2010.06.011","openalexId":"W2028415754","cited":7966,"byYear":{"2012":368,"2013":363,"2014":389,"2015":407,"2016":379,"2017":383,"2018":374,"2019":429,"2020":412,"2021":516,"2022":425,"2023":411,"2024":384,"2025":290,"2026":208},"year":2010,"title":"Cell Signaling by Receptor Tyrosine Kinases"},"paper-levine-p53-gatekeeper-cell-1997":{"doi":"10.1016/s0092-8674(00)81871-1","openalexId":"W1991494214","cited":7740,"byYear":{"2012":266,"2013":248,"2014":228,"2015":172,"2016":184,"2017":167,"2018":145,"2019":165,"2020":168,"2021":141,"2022":127,"2023":143,"2024":110,"2025":96,"2026":65},"year":1997,"title":"p53, the Cellular Gatekeeper for Growth and Division"},"paper-rahib-projecting-cancer-deaths-2030-cancerres-2014":{"doi":"10.1158/0008-5472.can-14-0155","openalexId":"W1968812902","cited":7332,"byYear":{"2013":2,"2014":39,"2015":186,"2016":340,"2017":421,"2018":568,"2019":718,"2020":922,"2021":958,"2022":863,"2023":839,"2024":690,"2025":512,"2026":262},"year":2014,"title":"Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States"},"paper-sato-lgr5-organoids-nature-2009":{"doi":"10.1038/nature07935","openalexId":"W1965157206","cited":7305,"byYear":{"2012":159,"2013":201,"2014":220,"2015":260,"2016":341,"2017":400,"2018":453,"2019":440,"2020":675,"2021":701,"2022":660,"2023":700,"2024":714,"2025":674,"2026":445},"year":2009,"title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche"},"paper-ribas-wolchok-checkpoint-blockade-science-2018":{"doi":"10.1126/science.aar4060","openalexId":"W2791483720","cited":6922,"byYear":{"2016":1,"2018":164,"2019":576,"2020":814,"2021":969,"2022":1019,"2023":961,"2024":986,"2025":830,"2026":599},"year":2018,"title":"Cancer immunotherapy using checkpoint blockade"},"paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013":{"doi":"10.1056/nejmoa1304369","openalexId":"W2165480504","cited":6811,"byYear":{"2012":1,"2013":15,"2014":267,"2015":422,"2016":423,"2017":512,"2018":550,"2019":538,"2020":658,"2021":701,"2022":635,"2023":639,"2024":583,"2025":501,"2026":351},"year":2013,"title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine"},"paper-le-mmr-deficiency-science-2017":{"doi":"10.1126/science.aan6733","openalexId":"W2622499649","cited":6783,"byYear":{"2013":1,"2015":3,"2017":129,"2018":608,"2019":744,"2020":932,"2021":969,"2022":948,"2023":819,"2024":704,"2025":536,"2026":381},"year":2017,"title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade"},"paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017":{"doi":"10.1158/0008-5472.can-17-0307","openalexId":"W2765224588","cited":6635,"byYear":{"2018":18,"2019":106,"2020":640,"2021":1319,"2022":1479,"2023":1217,"2024":1120,"2025":535,"2026":198},"year":2017,"title":"TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells"},"paper-li-timer2-nar-2020":{"doi":"10.1093/nar/gkaa407","openalexId":"W3027286012","cited":5783,"byYear":{"2019":1,"2020":39,"2021":626,"2022":1292,"2023":1216,"2024":1317,"2025":909,"2026":381},"year":2020,"title":"TIMER2.0 for analysis of tumor-infiltrating immune cells"},"paper-maude-ctl019-all-nejm-2014":{"doi":"10.1056/nejmoa1407222","openalexId":"W2118796952","cited":5479,"byYear":{"2012":4,"2013":3,"2014":24,"2015":262,"2016":385,"2017":543,"2018":503,"2019":540,"2020":690,"2021":573,"2022":507,"2023":524,"2024":394,"2025":320,"2026":197},"year":2014,"title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia"},"paper-pacific-nejm-2017":{"doi":"10.1056/nejmoa1709937","openalexId":"W2753065806","cited":4642,"byYear":{"2013":1,"2014":1,"2017":47,"2018":453,"2019":465,"2020":580,"2021":644,"2022":569,"2023":552,"2024":541,"2025":468,"2026":317},"year":2017,"title":"Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer"},"paper-leach-allison-ctla4-blockade-science-1996":{"doi":"10.1126/science.271.5256.1734","openalexId":"W2094366129","cited":3951,"byYear":{"2012":86,"2013":111,"2014":90,"2015":187,"2016":203,"2017":214,"2018":239,"2019":309,"2020":340,"2021":316,"2022":260,"2023":274,"2024":265,"2025":212,"2026":96},"year":1996,"title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade"},"paper-nelson-nejm-2020":{"doi":"10.1056/nejmoa1911793","openalexId":"W3003415550","cited":3660,"byYear":{"2012":1,"2020":281,"2021":503,"2022":550,"2023":613,"2024":611,"2025":635,"2026":459},"year":2020,"title":"Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial"},"paper-minnesota-fobt-nejm-1993":{"doi":"10.1056/nejm199305133281901","openalexId":"W2046686567","cited":3266,"byYear":{"2012":126,"2013":121,"2014":116,"2015":115,"2016":87,"2017":90,"2018":74,"2019":74,"2020":68,"2021":71,"2022":63,"2023":55,"2024":58,"2025":38,"2026":21},"year":1993,"title":"Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood"},"paper-ostrem-kras-g12c-nature-2013":{"doi":"10.1038/nature12796","openalexId":"W2128339707","cited":2572,"byYear":{"2013":2,"2014":85,"2015":109,"2016":133,"2017":121,"2018":123,"2019":140,"2020":196,"2021":241,"2022":303,"2023":283,"2024":321,"2025":285,"2026":225},"year":2013,"title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions"},"paper-paola-1-nejm-2019":{"doi":"10.1056/nejmoa1911361","openalexId":"W2994977341","cited":2100,"byYear":{"2019":1,"2020":179,"2021":320,"2022":374,"2023":396,"2024":346,"2025":278,"2026":200},"year":2019,"title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer"},"paper-relativity-047-nejm-2022":{"doi":"10.1056/nejmoa2109970","openalexId":"W4206239577","cited":1875,"byYear":{"2022":274,"2023":415,"2024":493,"2025":401,"2026":292},"year":2022,"title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma"},"paper-martincorena-somatic-mutations-normal-skin-science-2015":{"doi":"10.1126/science.aaa6806","openalexId":"W1956871134","cited":1867,"byYear":{"2014":2,"2015":34,"2016":121,"2017":157,"2018":149,"2019":191,"2020":218,"2021":215,"2022":205,"2023":175,"2024":166,"2025":143,"2026":89},"year":2015,"title":"High burden and pervasive positive selection of somatic mutations in normal human skin"},"paper-olympia-nejm-2021":{"doi":"10.1056/nejmoa2105215","openalexId":"W3165576985","cited":1730,"byYear":{"2021":89,"2022":330,"2023":376,"2024":383,"2025":341,"2026":208},"year":2021,"title":"Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer"},"paper-brca-risk-reducing-surgery-jama-2010":{"doi":"10.1001/jama.2010.1237","openalexId":"W2117576401","cited":1498,"byYear":{"2012":80,"2013":82,"2014":103,"2015":91,"2016":116,"2017":126,"2018":102,"2019":120,"2020":110,"2021":95,"2022":63,"2023":98,"2024":92,"2025":68,"2026":53},"year":2010,"title":"Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality"},"paper-majestec-1-teclistamab-nejm-2022":{"doi":"10.1056/nejmoa2203478","openalexId":"W4282033105","cited":1232,"byYear":{"2013":1,"2022":39,"2023":236,"2024":330,"2025":344,"2026":279},"year":2022,"title":"Teclistamab in Relapsed or Refractory Multiple Myeloma"},"paper-maia-daratumumab-rd-nejm-2019":{"doi":"10.1056/nejmoa1817249","openalexId":"W2947874495","cited":1019,"byYear":{"2012":1,"2018":1,"2019":39,"2020":194,"2021":209,"2022":146,"2023":130,"2024":110,"2025":110,"2026":75},"year":2019,"title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma"},"paper-murano-venetoclax-rituximab-nejm-2018":{"doi":"10.1056/nejmoa1713976","openalexId":"W2792666902","cited":932,"byYear":{"2013":1,"2017":1,"2018":52,"2019":133,"2020":132,"2021":144,"2022":123,"2023":111,"2024":104,"2025":78,"2026":52},"year":2018,"title":"Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia"},"paper-polarix-polatuzumab-rchp-nejm-2022":{"doi":"10.1056/nejmoa2115304","openalexId":"W4200197309","cited":922,"byYear":{"2020":1,"2022":84,"2023":164,"2024":205,"2025":259,"2026":209},"year":2021,"title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma"},"paper-ruby-nejm-2023":{"doi":"10.1056/nejmoa2216334","openalexId":"W4360991857","cited":861,"byYear":{"2021":1,"2023":117,"2024":283,"2025":295,"2026":165},"year":2023,"title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer"},"paper-nordicc-nejm-2022":{"doi":"10.1056/nejmoa2208375","openalexId":"W4303940405","cited":813,"byYear":{"2012":1,"2022":10,"2023":184,"2024":255,"2025":228,"2026":134},"year":2022,"title":"Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death"},"paper-keynote-564-nejm-2021":{"doi":"10.1056/nejmoa2106391","openalexId":"W3196207248","cited":786,"byYear":{"2021":26,"2022":200,"2023":175,"2024":152,"2025":136,"2026":95},"year":2021,"title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma"},"paper-rohaas-til-vs-ipilimumab-nejm-2022":{"doi":"10.1056/nejmoa2210233","openalexId":"W4311584464","cited":572,"byYear":{"2022":6,"2023":95,"2024":164,"2025":189,"2026":118},"year":2022,"title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma"},"paper-perseus-dara-vrd-transplant-nejm-2024":{"doi":"10.1056/nejmoa2312054","openalexId":"W4389606680","cited":571,"byYear":{"2023":3,"2024":150,"2025":253,"2026":164},"year":2023,"title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma"},"paper-masai-lancet-oncol-2023":{"doi":"10.1016/s1470-2045(23)00298-x","openalexId":"W4385448527","cited":564,"byYear":{"2022":1,"2023":32,"2024":169,"2025":207,"2026":155},"year":2023,"title":"Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study"},"paper-nadina-nejm-2024":{"doi":"10.1056/nejmoa2402604","openalexId":"W4399274678","cited":524,"byYear":{"2024":68,"2025":267,"2026":189},"year":2024,"title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma"},"paper-predimed-breast-jama-im-2015":{"doi":"10.1001/jamainternmed.2015.4838","openalexId":"W2155215362","cited":521,"byYear":{"2015":6,"2016":31,"2017":42,"2018":59,"2019":45,"2020":49,"2021":74,"2022":52,"2023":55,"2024":43,"2025":35,"2026":28},"year":2015,"title":"Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial"},"paper-niche-2-nejm-2024":{"doi":"10.1056/nejmoa2400634","openalexId":"W4399369796","cited":465,"byYear":{"2024":61,"2025":207,"2026":197},"year":2024,"title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer"},"paper-mariposa-nejm-2024":{"doi":"10.1056/nejmoa2403614","openalexId":"W4400029774","cited":447,"byYear":{"2023":1,"2024":39,"2025":236,"2026":171},"year":2024,"title":"Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC"},"paper-prasad-surrogate-endpoints-jama-im-2015":{"doi":"10.1001/jamainternmed.2015.2829","openalexId":"W1570249624","cited":403,"byYear":{"2013":1,"2015":7,"2016":24,"2017":32,"2018":38,"2019":40,"2020":27,"2021":38,"2022":38,"2023":43,"2024":50,"2025":33,"2026":31},"year":2015,"title":"The Strength of Association Between Surrogate End Points and Survival in Oncology"},"paper-niagara-nejm-2024":{"doi":"10.1056/nejmoa2408154","openalexId":"W4402552345","cited":396,"byYear":{"2024":14,"2025":192,"2026":190},"year":2024,"title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer"},"paper-pathfinder-lancet-2023":{"doi":"10.1016/s0140-6736(23)01700-2","openalexId":"W4387381160","cited":391,"byYear":{"2023":6,"2024":116,"2025":147,"2026":122},"year":2023,"title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study"},"paper-natalee-nejm-2024":{"doi":"10.1056/nejmoa2305488","openalexId":"W4392977246","cited":391,"byYear":{"2023":2,"2024":78,"2025":196,"2026":115},"year":2024,"title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer"},"paper-reproducibility-project-cancer-biology-elife-2021":{"doi":"10.7554/elife.71601","openalexId":"W4200247206","cited":388,"byYear":{"2021":8,"2022":72,"2023":117,"2024":69,"2025":74,"2026":47},"year":2021,"title":"Investigating the replicability of preclinical cancer biology"},"paper-patil-low-dose-nivolumab-jco-2023":{"doi":"10.1200/jco.22.01015","openalexId":"W4306921237","cited":217,"byYear":{"2022":6,"2023":51,"2024":63,"2025":55,"2026":42},"year":2022,"title":"Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study"},"paper-nhs-galleri-design-cancers-2022":{"doi":"10.3390/cancers14194818","openalexId":"W4303613649","cited":184,"byYear":{"2022":3,"2023":32,"2024":58,"2025":51,"2026":40},"year":2022,"title":"Cell-Free DNA–Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial"},"paper-sung-globocan-2020-cacancer-2021":{"doi":"10.3322/caac.21660","openalexId":"W3128646645","cited":114173,"byYear":{"2012":4,"2013":3,"2014":4,"2016":2,"2017":2,"2018":8,"2019":11,"2020":28,"2021":6887,"2022":22916,"2023":29439,"2024":32428,"2025":17182,"2026":5121},"year":2021,"title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries"},"paper-hallmarks-of-cancer-cell-2000":{"doi":"10.1016/s0092-8674(00)81683-9","openalexId":"W2034269086","cited":28710,"byYear":{"2012":1474,"2013":1396,"2014":1404,"2015":1342,"2016":1193,"2017":1158,"2018":1067,"2019":1064,"2020":1196,"2021":1249,"2022":1161,"2023":1007,"2024":964,"2025":826,"2026":385},"year":2000,"title":"The Hallmarks of Cancer"},"paper-torre-global-cancer-statistics-2012-cacancer-2015":{"doi":"10.3322/caac.21262","openalexId":"W2917837889","cited":27417,"byYear":{"2012":16,"2013":14,"2014":14,"2015":750,"2016":2929,"2017":4242,"2018":4786,"2019":4213,"2020":3446,"2021":2733,"2022":1670,"2023":1162,"2024":840,"2025":437,"2026":90},"year":2015,"title":"Global cancer statistics, 2012"},"paper-stupp-temozolomide-nejm-2005":{"doi":"10.1056/nejmoa043330","openalexId":"W2096287682","cited":22037,"byYear":{"2012":873,"2013":904,"2014":1019,"2015":1113,"2016":1066,"2017":1154,"2018":1165,"2019":1279,"2020":1483,"2021":1679,"2022":1595,"2023":1591,"2024":1589,"2025":1399,"2026":1030},"year":2005,"title":"Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma"},"paper-siegel-cancer-statistics-2019-cacancer-2019":{"doi":"10.3322/caac.21551","openalexId":"W2911188335","cited":21023,"byYear":{"2012":1,"2013":1,"2016":1,"2017":6,"2018":5,"2019":2365,"2020":6455,"2021":5015,"2022":2914,"2023":1960,"2024":1454,"2025":658,"2026":169},"year":2019,"title":"Cancer statistics, 2019"},"paper-siegel-cancer-statistics-2022-cacancer-2022":{"doi":"10.3322/caac.21708","openalexId":"W4206841660","cited":18329,"byYear":{"2016":1,"2020":1,"2021":5,"2022":3392,"2023":7039,"2024":5243,"2025":2088,"2026":540},"year":2022,"title":"Cancer statistics, 2022"},"paper-siegel-cancer-statistics-2021-cacancer-2021":{"doi":"10.3322/caac.21654","openalexId":"W3119005666","cited":17445,"byYear":{"2012":1,"2014":1,"2018":4,"2019":1,"2020":6,"2021":2804,"2022":6115,"2023":4237,"2024":2842,"2025":1171,"2026":253},"year":2021,"title":"Cancer Statistics, 2021"},"paper-siegel-cancer-statistics-2018-cacancer-2018":{"doi":"10.3322/caac.21442","openalexId":"W2781525129","cited":17040,"byYear":{"2012":1,"2013":2,"2014":1,"2015":1,"2017":7,"2018":2267,"2019":4820,"2020":3489,"2021":2303,"2022":1511,"2023":1003,"2024":947,"2025":532,"2026":136},"year":2018,"title":"Cancer statistics, 2018"},"paper-siegel-cancer-statistics-2023-cacancer-2023":{"doi":"10.3322/caac.21763","openalexId":"W4315754639","cited":16971,"byYear":{"2014":1,"2017":2,"2020":2,"2021":2,"2022":9,"2023":3565,"2024":8281,"2025":4061,"2026":1042},"year":2023,"title":"Cancer statistics, 2023"},"paper-siegel-cancer-statistics-2016-cacancer-2016":{"doi":"10.3322/caac.21332","openalexId":"W2235523093","cited":16184,"byYear":{"2012":1,"2013":3,"2014":28,"2015":38,"2016":1696,"2017":4329,"2018":3120,"2019":2010,"2020":1630,"2021":1257,"2022":821,"2023":591,"2024":381,"2025":215,"2026":45},"year":2016,"title":"Cancer statistics, 2016"},"paper-therasse-recist-jnci-2000":{"doi":"10.1093/jnci/92.3.205","openalexId":"W2139248078","cited":15759,"byYear":{"2012":1225,"2013":1189,"2014":1057,"2015":883,"2016":715,"2017":626,"2018":450,"2019":402,"2020":386,"2021":397,"2022":319,"2023":266,"2024":191,"2025":149,"2026":74},"year":2000,"title":"New Guidelines to Evaluate the Response to Treatment in Solid Tumors"},"paper-siegel-cancer-statistics-2017-cacancer-2017":{"doi":"10.3322/caac.21387","openalexId":"W2570618306","cited":14990,"byYear":{"2013":3,"2015":3,"2016":2,"2017":1841,"2018":4332,"2019":3268,"2020":2138,"2021":1273,"2022":894,"2023":532,"2024":453,"2025":180,"2026":44},"year":2017,"title":"Cancer statistics, 2017"},"paper-topalian-anti-pd1-nejm-2012":{"doi":"10.1056/nejmoa1200690","openalexId":"W2160834915","cited":12806,"byYear":{"2012":139,"2013":631,"2014":815,"2015":1064,"2016":1206,"2017":1245,"2018":1075,"2019":1060,"2020":1201,"2021":984,"2022":881,"2023":856,"2024":702,"2025":565,"2026":352},"year":2012,"title":"Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer"},"paper-siegel-cancer-statistics-2015-cacancer-2015":{"doi":"10.3322/caac.21254","openalexId":"W2170552969","cited":11932,"byYear":{"2012":1,"2013":2,"2014":7,"2015":1449,"2016":3303,"2017":2369,"2018":1361,"2019":1021,"2020":778,"2021":591,"2022":435,"2023":278,"2024":194,"2025":103,"2026":24},"year":2015,"title":"Cancer statistics, 2015"},"paper-siegel-cancer-statistics-2013-cacancer-2013":{"doi":"10.3322/caac.21166","openalexId":"W2161817637","cited":11913,"byYear":{"2012":16,"2013":1228,"2014":3157,"2015":2145,"2016":1359,"2017":1052,"2018":754,"2019":612,"2020":443,"2021":348,"2022":241,"2023":192,"2024":222,"2025":97,"2026":17},"year":2013,"title":"Cancer statistics, 2013"},"paper-slamon-her2-amplification-science-1987":{"doi":"10.1126/science.3798106","openalexId":"W2141393790","cited":11812,"byYear":{"2012":461,"2013":546,"2014":483,"2015":435,"2016":415,"2017":394,"2018":341,"2019":316,"2020":336,"2021":348,"2022":312,"2023":340,"2024":323,"2025":229,"2026":174},"year":1987,"title":"Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene"},"paper-slamon-trastuzumab-nejm-2001":{"doi":"10.1056/nejm200103153441101","openalexId":"W2318605753","cited":11599,"byYear":{"2012":565,"2013":604,"2014":593,"2015":567,"2016":539,"2017":491,"2018":467,"2019":428,"2020":448,"2021":401,"2022":421,"2023":452,"2024":412,"2025":292,"2026":196},"year":2001,"title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2"},"paper-siegel-cancer-statistics-2014-cacancer-2014":{"doi":"10.3322/caac.21208","openalexId":"W2169961966","cited":11579,"byYear":{"2012":4,"2013":4,"2014":1379,"2015":3283,"2016":2077,"2017":1284,"2018":904,"2019":681,"2020":571,"2021":399,"2022":336,"2023":264,"2024":233,"2025":106,"2026":24},"year":2014,"title":"Cancer statistics, 2014"},"paper-siegel-cancer-statistics-2012-cacancer-2012":{"doi":"10.3322/caac.20138","openalexId":"W2165948908","cited":10722,"byYear":{"2012":1179,"2013":2838,"2014":2041,"2015":1327,"2016":811,"2017":654,"2018":475,"2019":374,"2020":298,"2021":262,"2022":173,"2023":123,"2024":87,"2025":42,"2026":14},"year":2012,"title":"Cancer statistics, 2012"},"paper-siegel-cancer-statistics-2024-cacancer-2024":{"doi":"10.3322/caac.21820","openalexId":"W4390946922","cited":9418,"byYear":{"2021":3,"2022":1,"2023":3,"2024":2887,"2025":5084,"2026":1437},"year":2024,"title":"Cancer statistics, 2024"},"paper-veber-oral-bioavailability-jmedchem-2002":{"doi":"10.1021/jm020017n","openalexId":"W2105649494","cited":8360,"byYear":{"2012":150,"2013":169,"2014":196,"2015":181,"2016":237,"2017":262,"2018":355,"2019":407,"2020":572,"2021":724,"2022":866,"2023":873,"2024":912,"2025":912,"2026":704},"year":2002,"title":"Molecular Properties That Influence the Oral Bioavailability of Drug Candidates"},"paper-temel-early-palliative-care-nejm-2010":{"doi":"10.1056/nejmoa1000678","openalexId":"W2147016542","cited":7549,"byYear":{"2012":359,"2013":404,"2014":453,"2015":478,"2016":531,"2017":599,"2018":541,"2019":525,"2020":547,"2021":544,"2022":520,"2023":470,"2024":486,"2025":417,"2026":326},"year":2010,"title":"Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer"},"paper-singh-brain-tumour-initiating-cells-nature-2004":{"doi":"10.1038/nature03128","openalexId":"W2001544973","cited":7454,"byYear":{"2012":521,"2013":521,"2014":437,"2015":441,"2016":410,"2017":392,"2018":306,"2019":323,"2020":328,"2021":330,"2022":296,"2023":266,"2024":200,"2025":173,"2026":106},"year":2004,"title":"Identification of human brain tumour initiating cells"},"paper-toga-trastuzumab-gastric-lancet-2010":{"doi":"10.1016/s0140-6736(10)61121-x","openalexId":"W2100439220","cited":7380,"byYear":{"2012":293,"2013":405,"2014":509,"2015":487,"2016":475,"2017":528,"2018":483,"2019":480,"2020":514,"2021":535,"2022":552,"2023":532,"2024":569,"2025":442,"2026":269},"year":2010,"title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial"},"paper-yarden-sliwkowski-erbb-network-nrmcb-2001":{"doi":"10.1038/35052073","openalexId":"W1964321121","cited":7029,"byYear":{"2012":380,"2013":414,"2014":321,"2015":319,"2016":278,"2017":257,"2018":261,"2019":211,"2020":240,"2021":271,"2022":265,"2023":279,"2024":243,"2025":182,"2026":172},"year":2001,"title":"Untangling the ErbB signalling network"},"paper-slamon-her2-breast-ovarian-science-1989":{"doi":"10.1126/science.2470152","openalexId":"W2095156669","cited":6868,"byYear":{"2012":236,"2013":247,"2014":208,"2015":220,"2016":160,"2017":164,"2018":140,"2019":110,"2020":146,"2021":169,"2022":130,"2023":152,"2024":121,"2025":75,"2026":47},"year":1989,"title":"Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer"},"paper-tumeh-pd1-adaptive-immune-resistance-nature-2014":{"doi":"10.1038/nature13954","openalexId":"W2039123767","cited":6718,"byYear":{"2012":1,"2013":2,"2014":12,"2015":302,"2016":487,"2017":567,"2018":588,"2019":614,"2020":820,"2021":806,"2022":731,"2023":622,"2024":540,"2025":396,"2026":216},"year":2014,"title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance"},"paper-thiery-emt-tumour-progression-nrc-2002":{"doi":"10.1038/nrc822","openalexId":"W2076583198","cited":6710,"byYear":{"2012":432,"2013":390,"2014":441,"2015":411,"2016":428,"2017":449,"2018":363,"2019":334,"2020":294,"2021":320,"2022":267,"2023":215,"2024":224,"2025":100,"2026":57},"year":2002,"title":"Epithelial–mesenchymal transitions in tumour progression"},"paper-vogelstein-surfing-p53-network-nature-2000":{"doi":"10.1038/35042675","openalexId":"W1650797637","cited":6633,"byYear":{"2012":333,"2013":332,"2014":330,"2015":289,"2016":246,"2017":236,"2018":215,"2019":224,"2020":225,"2021":226,"2022":207,"2023":153,"2024":144,"2025":94,"2026":57},"year":2000,"title":"Surfing the p53 network"},"paper-schreiber-cancer-immunoediting-science-2011":{"doi":"10.1126/science.1203486","openalexId":"W2004630197","cited":6510,"byYear":{"2012":222,"2013":315,"2014":273,"2015":368,"2016":424,"2017":432,"2018":402,"2019":478,"2020":577,"2021":629,"2022":585,"2023":581,"2024":499,"2025":374,"2026":280},"year":2011,"title":"Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion"},"paper-thorsson-immune-landscape-of-cancer-immunity-2018":{"doi":"10.1016/j.immuni.2018.03.023","openalexId":"W2796207838","cited":6320,"byYear":{"2017":2,"2018":104,"2019":302,"2020":597,"2021":1043,"2022":1243,"2023":1045,"2024":992,"2025":624,"2026":366},"year":2018,"title":"The Immune Landscape of Cancer"},"paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004":{"doi":"10.1056/nejmoa040694","openalexId":"W2125452425","cited":6111,"byYear":{"2012":345,"2013":337,"2014":342,"2015":347,"2016":292,"2017":300,"2018":304,"2019":327,"2020":334,"2021":330,"2022":321,"2023":305,"2024":243,"2025":206,"2026":142},"year":2004,"title":"Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer"},"paper-solo-1-nejm-2018":{"doi":"10.1056/nejmoa1810858","openalexId":"W2897430921","cited":2915,"byYear":{"2013":1,"2017":1,"2018":16,"2019":227,"2020":414,"2021":458,"2022":428,"2023":431,"2024":378,"2025":323,"2026":230},"year":2018,"title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer"},"paper-viale-a-venetoclax-azacitidine-nejm-2020":{"doi":"10.1056/nejmoa2012971","openalexId":"W3048827006","cited":2908,"byYear":{"2014":1,"2019":2,"2020":69,"2021":366,"2022":459,"2023":541,"2024":544,"2025":541,"2026":375},"year":2020,"title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia"},"paper-vision-nejm-2021":{"doi":"10.1056/nejmoa2107322","openalexId":"W3176208875","cited":2796,"byYear":{"2012":1,"2014":1,"2021":109,"2022":389,"2023":518,"2024":594,"2025":621,"2026":562},"year":2021,"title":"Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer"},"paper-tcga-pancancer-atlas-cell-2018":{"doi":"10.1016/j.cell.2018.03.022","openalexId":"W2796153844","cited":2773,"byYear":{"2013":1,"2018":70,"2019":199,"2020":371,"2021":433,"2022":408,"2023":390,"2024":365,"2025":305,"2026":228},"year":2018,"title":"Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer"},"paper-protac-concept-sakamoto-pnas-2001":{"doi":"10.1073/pnas.141230798","openalexId":"W2151683271","cited":2544,"byYear":{"2012":10,"2013":9,"2014":13,"2015":15,"2016":27,"2017":47,"2018":80,"2019":118,"2020":201,"2021":230,"2022":300,"2023":321,"2024":388,"2025":421,"2026":264},"year":2001,"title":"Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation"},"paper-tracerx-100-nejm-2017":{"doi":"10.1056/nejmoa1616288","openalexId":"W2609243345","cited":2493,"byYear":{"2016":1,"2017":89,"2018":236,"2019":288,"2020":359,"2021":357,"2022":341,"2023":268,"2024":234,"2025":179,"2026":135},"year":2017,"title":"Tracking the Evolution of Non–Small-Cell Lung Cancer"},"paper-stampede-abiraterone-nejm-2017":{"doi":"10.1056/nejmoa1702900","openalexId":"W2620746860","cited":1803,"byYear":{"2015":1,"2016":1,"2017":95,"2018":240,"2019":234,"2020":225,"2021":221,"2022":194,"2023":175,"2024":164,"2025":162,"2026":87},"year":2017,"title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy"},"paper-hpv-vaccine-sweden-nejm-2020":{"doi":"10.1056/nejmoa1917338","openalexId":"W3090300247","cited":1507,"byYear":{"2020":13,"2021":269,"2022":254,"2023":277,"2024":254,"2025":263,"2026":172},"year":2020,"title":"HPV Vaccination and the Risk of Invasive Cervical Cancer"},"paper-hpv-self-sampling-bmj-2018":{"doi":"10.1136/bmj.k4823","openalexId":"W2902810541","cited":902,"byYear":{"2019":41,"2020":97,"2021":106,"2022":130,"2023":145,"2024":155,"2025":142,"2026":85},"year":2018,"title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses"},"paper-unger-trial-participation-barriers-jnci-2019":{"doi":"10.1093/jnci/djy221","openalexId":"W2915663023","cited":582,"byYear":{"2019":17,"2020":46,"2021":73,"2022":83,"2023":82,"2024":114,"2025":92,"2026":74},"year":2018,"title":"Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation"},"paper-johnson-alternative-medicine-jnci-2018":{"doi":"10.1093/jnci/djx145","openalexId":"W2743558319","cited":336,"byYear":{"2017":9,"2018":31,"2019":36,"2020":38,"2021":34,"2022":42,"2023":42,"2024":36,"2025":39,"2026":28},"year":2017,"title":"Use of Alternative Medicine for Cancer and Its Impact on Survival"},"paper-basu-single-dose-hpv-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00453-8","openalexId":"W3204615344","cited":267,"byYear":{"2021":9,"2022":41,"2023":47,"2024":75,"2025":64,"2026":31},"year":2021,"title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study"},"paper-swog-s1826-nivolumab-avd-nejm-2024":{"doi":"10.1056/nejmoa2405888","openalexId":"W4403462752","cited":244,"byYear":{"2020":1,"2024":9,"2025":121,"2026":113},"year":2024,"title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma"},"paper-scalp-trial-jama-2017":{"doi":"10.1001/jama.2016.20939","openalexId":"W2588306525","cited":234,"byYear":{"2017":16,"2018":24,"2019":26,"2020":37,"2021":26,"2022":16,"2023":17,"2024":29,"2025":19,"2026":21},"year":2017,"title":"Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer"},"paper-badwe-progesterone-jco-2011":{"doi":"10.1200/jco.2010.33.0738","openalexId":"W2152752482","cited":89,"byYear":{"2012":5,"2013":2,"2014":4,"2015":6,"2016":17,"2017":7,"2018":10,"2019":2,"2020":7,"2021":8,"2022":6,"2023":8,"2024":4,"2025":1},"year":2011,"title":"Single-Injection Depot Progesterone Before Surgery and Survival in Women With Operable Breast Cancer: A Randomized Controlled Trial"},"paper-jain-talicabtagene-lancet-haem-2025":{"doi":"10.1016/s2352-3026(24)00377-6","openalexId":"W4408392398","cited":16,"byYear":{"2025":6,"2026":10},"year":2025,"title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study"},"paper-sherr-roberts-cdk-inhibitors-genesdev-1999":{"doi":"10.1101/gad.13.12.1501","openalexId":"W2121619780","cited":6129,"byYear":{"2012":258,"2013":230,"2014":205,"2015":206,"2016":154,"2017":162,"2018":142,"2019":138,"2020":153,"2021":155,"2022":137,"2023":126,"2024":101,"2025":99,"2026":54},"year":1999,"title":"CDK inhibitors: positive and negative regulators of G1-phase progression"},"paper-zuma-1-axi-cel-nejm-2017":{"doi":"10.1056/nejmoa1707447","openalexId":"W2773804840","cited":6089,"byYear":{"2012":2,"2013":2,"2016":2,"2017":4,"2018":264,"2019":483,"2020":715,"2021":859,"2022":902,"2023":800,"2024":804,"2025":735,"2026":498},"year":2017,"title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma"},"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020":{"doi":"10.1056/nejmoa1914347","openalexId":"W3014583893","cited":1866,"byYear":{"2012":1,"2020":81,"2021":328,"2022":370,"2023":330,"2024":331,"2025":247,"2026":172},"year":2020,"title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma"},"paper-zuma-7-axi-cel-second-line-nejm-2022":{"doi":"10.1056/nejmoa2116133","openalexId":"W4200201081","cited":1605,"byYear":{"2013":1,"2021":1,"2022":216,"2023":354,"2024":411,"2025":385,"2026":235},"year":2021,"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma"}},"missing":["paper-cercek-dostarlimab-rectal-nejm-2022","paper-tracerx-evolution-nature-2023"]}